MannKind Co. (NASDAQ:MNKD) Receives Consensus Rating of “Buy” from Analysts

MannKind Co. (NASDAQ:MNKD) has received a consensus recommendation of “Buy” from the eight brokerages that are currently covering the stock, MarketBeat.com reports. Seven analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $9.21.

Several research firms have commented on MNKD. StockNews.com upgraded MannKind from a “hold” rating to a “buy” rating in a research report on Friday, March 7th. Wedbush restated an “outperform” rating and set a $11.00 price target on shares of MannKind in a research report on Thursday, February 27th. Wells Fargo & Company assumed coverage on shares of MannKind in a report on Friday, December 20th. They issued an “overweight” rating and a $9.00 price objective for the company. Finally, Royal Bank of Canada upgraded MannKind from a “sector perform” rating to an “outperform” rating and raised their target price for the company from $7.00 to $10.00 in a research report on Thursday, December 19th.

Hedge Funds Weigh In On MannKind

Hedge funds and other institutional investors have recently made changes to their positions in the company. GF Fund Management CO. LTD. acquired a new position in MannKind in the 4th quarter valued at $37,000. Jones Financial Companies Lllp lifted its stake in shares of MannKind by 3,294.8% in the fourth quarter. Jones Financial Companies Lllp now owns 6,586 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 6,392 shares in the last quarter. Kovitz Investment Group Partners LLC acquired a new position in MannKind during the fourth quarter worth about $65,000. Beirne Wealth Consulting Services LLC purchased a new stake in MannKind during the 4th quarter valued at about $66,000. Finally, Marshall Investment Management LLC acquired a new stake in MannKind in the 4th quarter valued at about $69,000. Hedge funds and other institutional investors own 49.55% of the company’s stock.

MannKind Price Performance

NASDAQ:MNKD opened at $5.20 on Friday. The company’s fifty day moving average price is $5.67 and its 200-day moving average price is $6.27. MannKind has a 1-year low of $3.97 and a 1-year high of $7.63. The firm has a market capitalization of $1.58 billion, a P/E ratio of 74.29 and a beta of 1.27.

MannKind (NASDAQ:MNKD) last released its quarterly earnings data on Wednesday, February 26th. The biopharmaceutical company reported $0.03 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.03. MannKind had a negative return on equity of 17.74% and a net margin of 8.07%. The business had revenue of $76.78 million during the quarter, compared to analyst estimates of $74.99 million. Equities analysts anticipate that MannKind will post 0.1 EPS for the current fiscal year.

MannKind Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.